What is ORTHOCON?
ORTHOCON operates at the intersection of material science and surgical intervention, specializing in the development of first-in-class therapeutic devices. The company is best known for its MONTAGE product line, a cohesive and resorbable hemostatic bone putty that offers immediate adhesion to bleeding bone surfaces. This innovation is engineered to streamline surgical workflows across diverse specialties, including maxillofacial, cardiothoracic, and sports medicine applications. By focusing on materials that enhance surgical outcomes and simplify complex procedures, ORTHOCON has established a robust market position as a provider of essential tools for modern operating rooms.
How much funding has ORTHOCON raised?
ORTHOCON has raised a total of $35M across 2 funding rounds:
Series A
$10M
Series B
$25M
Series A (2006): $10M with participation from Canaan Partners and BB Biotech Ventures
Series B (2009): $25M led by Canaan Partners, BB Biotech Ventures, and ProQuest Investment
Key Investors in ORTHOCON
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
BB Biotech Ventures
BB BIOTECH VENTURES is a healthcare-dedicated venture capital firm that manages funds investing in private companies developing and marketing drugs and medical devices or providing healthcare services.
ProQuest Investment
ProQuest Investments IV, L.P. specializes in venture capital investments within the healthcare industry, typically focusing on North American companies with significant capital requirements.
What's next for ORTHOCON?
With the support of its institutional partners, ORTHOCON is well-positioned to expand its footprint in the global medical technology market. The current enterprise-level funding context suggests a strategic pivot toward broader commercialization and the potential for further R&D into next-generation resorbable materials. As the company continues to leverage its existing intellectual property, the focus will likely shift toward increasing market penetration in North American and international clinical settings. Future growth will depend on the firm's ability to maintain its competitive edge in material innovation while navigating the evolving regulatory requirements for surgical implants and therapeutic devices.
See full ORTHOCON company page
